On 2 September 2026 the FDA approved a supplement to NDA 213871 - Pfizer's abrocitinib, marketed as CIBINQO, the oral selective JAK1 inhibitor licensed for refractory moderate-to-severe atopic dermatitis. A supplemental approval alters an application that is already licensed and can cover manufacturing, labelling, presentation or an added population; the approval record names the application and sponsor and does not say which.
So the honest description is that something about an existing product has changed and the listing does not disclose what. It is not a new approval, and it is not evidence about efficacy. The place to look for a substantive change is the current US prescribing information.
What has not changed is the class position. Abrocitinib carries the JAK inhibitor boxed warning for serious infection, mortality, malignancy, major adverse cardiovascular events and thrombosis, derived from a rheumatoid arthritis population rather than from atopic dermatitis trials - a limitation worth stating to patients rather than passing over. The pre-treatment work-up and the ongoing monitoring, including tuberculosis screening in settings where latent infection is common, are unaffected by an administrative approval of this kind.
- Read this as a supplement to an existing application, not a new approval or indication.
- Check the current prescribing information rather than inferring what changed from the listing.
- The JAK class boxed warning stands, and its evidence base is a rheumatoid arthritis population, not atopic dermatitis.
- Screen for latent tuberculosis and viral hepatitis before starting, and keep to the lipid and blood count monitoring schedule.
- This is an FDA action and says nothing about CDSCO status or availability in India.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free